ArticleEuropean journal of nuclear medicine and molecular imaging2026
Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.
Claudia Leslie et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.